



PTO/SB/08a (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

Approved for use through September 2007 GPO:2007-090

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4 Attorney Docket Number 29248/21

Complete if Known

Application Number	10/803,793
Filing Date	March 18, 2004
First Named Inventor	Erik Buntinx
Art Unit	1612
Examiner Name	Benjamin J. Packard
Attorney Docket Number	29248/21

Sheet 1 of 4

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	3	DE 4039631	06-17-1992	Dr. Kerstin Bode-Greuel	Abstract	
	4	CA 2461248	09-08-2009	Pharmaneuroboost N.V.	Notice of Allowance	

Examiner Signature _____ **Date Considered** _____

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/803,793
				Filing Date	March 18, 2004
				First Named Inventor	Erik Buntinx
				Art Unit	1612
				Examiner Name	Benjamin J. Packard
Sheet	2	of	4	Attorney Docket Number	29248/21

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	5	NELSON, Craig J., et al., "Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials." Am J Psychiatry,	
		September 2009, 166:980-991.	
	6	PRINSSEN, Eric P.M. et al., "The effects of antipsychotics with 5-HT2C receptor affinity in behavioral assays selective for 5-HT2C receptor antagonist properties of	
		compounds." European Journal of Pharmacology, 2000, 388:57-67.	
	7	Download from www.whocc.no/atcddd/welcome.html dated 08/20/2009, 2 pages.	
	8	BUNTINX E et al., "Preclinical and Clinical Evidence for the Efficacy of Pipamperone in Augmenting the Antidepressant Effects of the SSRI Citalopram."	
		Poster presented at the XXVI Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress 13-17 July 2008, Munich, Germany and Summary Expected Receptor Occupancy (RO)	
		of Pipamperone in vivo.	
	9	Download, "Panic Attacks Anxiety Attacks Self-Help Anxieties OCD Social Anxiety Disorder." http://www.anxieties.com/med-intro.php, December 3, 2009, pp. 1-5.	
	10	WADE A G et al., "Addition of a Selective 5-HT2A/D4 Antagonist Accelerates the Antidepressant Effects of Citalopram," Poster presented 12/09/09, ACNP Hollywood, FL.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				<i>Complete if Known</i>
Substitute for form 1449/PTO				
				Application Number 10/803,793
				Filing Date March 18, 2004
				First Named Inventor Erik Buntinx
				Art Unit 1612
				Examiner Name Benjamin J. Packard
Sheet	3	of	4	Attorney Docket Number 29248/21

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	WIRZ-JUSTICE A et al., "Haloperidol Disrupts, Clozapine Reinstates the Circadian Rest-Activity Cycle in a Patient With Early-Onset Alzheimer Disease," Alzheimer Disease and Associated Disorders, Vol. 14, No. 4, pp. 212-215.	
	12	DECISION TO GRANT A EUROPEAN PATENT PURSUANT TO ARTICLE 97(1) EPC, dated February 19, 2009 in connection with EP Patent Application No. 04025035.9, 2 pages.	
	13	COMMUNICATION UNDER RULE 71(3) EPC, dated October 13, 2008 in connection with EP Patent Application No. 04025035.9, 95 pages.	
	14	INTERVIEW SUMMARY, dated October 22, 2009 in connection with U.S. Patent Application No. 10/725,965, 1 page.	
	15	CABASER 1 MG & 2 MG TABLETS - SUMMARY OF PRODUCT CHARACTERISTICS (SPC - ELECTRONIC MEDICINES COMPENDIUM (eMC), last updated on January 27, 2009, pp 1-11.	
	16	MIRAPEXIN 0.7 MG TABLETS - SUMMARY OF PRODUCT CHARACTERISTICS (SPC) - ELECTRONIC MEDICINES COMPENDIUM (eMC), updated October 26, 2009, pp. 1-16.	
	17	REQUIP TABLETS - SUMMARY OF PRODUCT CHARACTERISTICS (SPC) - ELECTRONIC MEDICINES COMPENDIUM (eMC), updated October 13, 2009, pp. 1-11.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/803,793
				Filing Date	March 18, 2004
				First Named Inventor	Erik Buntinx
				Art Unit	1612
				Examiner Name	Benjamin J. Packard
Sheet	4	of	4	Attorney Docket Number	29248/21

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	18	SYMMETREL CAPSULES - SUMMARY OF PRODUCT CHARACTERISTICS (SPC) - ELECTRONIC MEDICINES COMPENDIUM (eMC), updated February 26, 2008, pp. 1-9.		
	19	PARLODEL 5MG CAPSULES - SUMMARY OF PRODUCT CHARACTERISTICS (SPC) - ELECTRONIC MEDICINES COMPENDIUM (eMC), updated January 15, 2008, pp. 1-15.		
	20	LEVODOPA AND BENZERAZIDE (SYSTEMIC), revised September, 8, 2000, website Drugs.com http://www.drugs.com/cons/levodopa-and-benserazide.html?printable=1		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.